Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bismuth Subsalicylate
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Arcadia Consumer Healthcare
Deal Size : Undisclosed
Deal Type : Acquisition
Arcadia Consumer Healthcare Acquires Iconic Over-the-Counter Anti-Diarrheal Medicine Kaopectate®
Details : Acquisition further strengthens Arcadia's consumer healthcare product portfolio.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 20, 2020
Lead Product(s) : Bismuth Subsalicylate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Arcadia Consumer Healthcare
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Bismuth Subsalicylate
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : PROCTER AND GAMBLE
Deal Size : Inapplicable
Deal Type : Inapplicable
Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)
Details : Bismuth Subsalicylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diarrhea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 23, 2021
Lead Product(s) : Bismuth Subsalicylate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : PROCTER AND GAMBLE
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bismuth Subsalicylate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of Bismuth Subsalicylate in Clostridium Difficile Colitis
Details : Bismuth Subsalicylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Clostridium Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 19, 2018
Lead Product(s) : Bismuth Subsalicylate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bismuth Subsalicylate
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : PROCTER AND GAMBLE | The New York Center for Travel and Tropical Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea
Details : Bismuth Subsalicylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diarrhea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 24, 2018
Lead Product(s) : Bismuth Subsalicylate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : PROCTER AND GAMBLE | The New York Center for Travel and Tropical Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bismuth Subsalicylate
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : PROCTER AND GAMBLE | Health Oriented Preventive Education
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients--Pakistan
Details : Bismuth Subsalicylate is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Diarrhea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 28, 2014
Lead Product(s) : Bismuth Subsalicylate
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : PROCTER AND GAMBLE | Health Oriented Preventive Education
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bismuth Subsalicylate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bismuth Subsalicylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 05, 2013
Lead Product(s) : Bismuth Subsalicylate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable